Ascendis Pharma A/S (NASDAQ: ASND) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 17.03 | EPS (ttm) | 13.90 | Insider Own | 44.74% | Shs Outstand | 62.11M | Perf Week | -10.17% |
| Market Cap | 14.70B | Forward P/E | 22.69 | EPS next Y | 10.43 | Insider Trans | -0.07% | Shs Float | 61.56M | Perf Month | -8.82% |
| Enterprise Value | 14.29B | PEG | 0.03 | EPS next Q | 1.30 | Inst Own | - | Short Float | 6.83% | Perf Quarter | 2.55% |
| Income | 838.06M | P/S | 12.14 | EPS this Y | 22.76% | Inst Trans | - | Short Ratio | 6.43 | Perf Half Y | 5.76% |
| Sales | 1.21B | P/B | 9.23 | EPS next Y | -36.47% | ROA | 33.08% | Short Interest | 4.20M | Perf YTD | 11.01% |
| Book/sh | - | P/C | 37.74 | EPS next 5Y | 10.28% | ROE | 190.44% | 52W High | 282.15 -16.10% | Perf Year | 18.60% |
| Cash/sh | - | P/FCF | 37.99 | EPS past 3/5Y | - | ROIC | 5.80% | 52W Low | 186.06 27.23% | Perf 3Y | 136.18% |
| Dividend Est. | - | EV/EBITDA | 159.19 | Sales past 3/5Y | 143.54% 149.92% | Gross Margin | 90.19% | Volatility | 5.21% 3.55% | Perf 5Y | 53.28% |
| Dividend TTM | - | EV/Sales | 11.80 | EPS Y/Y TTM | 289.39% | Oper. Margin | 10.38% | ATR (14) | 10.08 | Perf 10Y | 1099.80% |
| Dividend Ex-Date | - | Quick Ratio | 2.32 | Sales Y/Y TTM | 212.72% | Profit Margin | 71.69% | RSI (14) | 37.11 | Recom | 2.08 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.99 | EPS Q/Q | 453.76% | SMA20 | -7.56% | Beta | 0.35 | Target Price | 326.00 |
| Payout | 0.00% | Debt/Eq | 0.31 | Sales Q/Q | 124.02% | SMA50 | -7.11% | Rel Volume | 2.17 | Prev Close | 239.04 |
| Employees | 1,189 | LT Debt/Eq | -2.37 | Earnings | Nov 11 | SMA200 | 0.98% | Avg Volume | 716.88K | Price | 236.72 |
| IPO Date | Jan 28, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 89.43% 1.21% | Net Debt/EBITDA | -4.63 | Volume | 1,558,665 | Change | -0.97% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-16-26 | Reiterated | UBS | Buy | $345 → $344 |
| Sep-15-26 | Downgrade | Raymond James | Strong Buy → Outperform | $287 |
| Sep-10-26 | Reiterated | H.C. Wainwright | Buy | $345 → $344 |
| Sep-01-26 | Reiterated | Morgan Stanley | Overweight | $275 → $273 |
| Aug-31-26 | Reiterated | Stifel Nicolaus | Buy | $328 → $326 |
| Aug-31-26 | Reiterated | UBS | Buy | $345 |
| Aug-31-26 | Reiterated | Jefferies | Buy | $333 → $330 |
| Aug-18-26 | Initiated | BMO Capital | Outperform | $319 |
| Aug-14-26 | Reiterated | Barclays | Overweight | $345 → $329 |
| Aug-14-26 | Reiterated | RBC Capital | Outperform | $280 → $290 |
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,229 | 780 | 393 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 121 | 116 | 48 | — | — | — | — | — | — | |
| Gross Profit | 1,109 | 664 | 346 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 660 | 492 | 308 | — | — | — | — | — | — | |
| Research and Development | 319 | 320 | 332 | — | — | — | — | — | — | |
| Other Operating Expense | 3 | 0 | 7 | — | — | — | — | — | — | |
| Operating Income | 128 | -148 | -302 | — | — | — | — | — | — | |
| Interest Expense | 191 | 87 | 71 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 180 | 5 | -31 | — | — | — | — | — | — | |
| Net Income Before Taxes | 117 | -230 | -404 | — | — | — | — | — | — | |
| Income Taxes | -767 | 17 | 5 | — | — | — | — | — | — | |
| Consolidated Net Income | 884 | -247 | -409 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 884 | -247 | -409 | — | — | — | — | — | — | |
| Net Income | 884 | -247 | -409 | — | — | — | — | — | — | |
| EPS (Recurring) | 14.14 | -4.08 | -7.06 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 14.14 | -4.08 | -7.06 | — | — | — | — | — | — | |
| EPS (Diluted) | 13.38 | -4.08 | -7.06 | — | — | — | — | — | — | |
| EBITDA | 91 | -124 | -314 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 17.69 | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 12.33 | 16.68 | 20.32 | — | — | — | — | — | — | |
| Gross Margin | 90.24 | 85.13 | 88.04 | — | — | — | — | — | — | |
| Operating Margin | 10.41 | -18.97 | -76.84 | — | — | — | — | — | — | |
| Net Margin | 71.93 | -31.67 | -104.07 | — | — | — | — | — | — | |
| Shares Outstanding | 64 | 61 | 58 | — | — | — | — | — | — | |
| Market Capitalization | 15,150 | 13,008 | 7,985 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Bodenhoff Mads | SVP & PAO | Sep 08 '26 | Option Exercise | 110.00 | 3,000 | 330,000 | 3,000 | Sep 09 |
| Bodenhoff Mads | SVP & PAO | Sep 08 '26 | Sale | 270.19 | 3,000 | 810,570 | 0 | Sep 09 |
| HOLTUG LARS | Director | Sep 02 '26 | Sale | 264.13 | 236 | 62,335 | 4,000 | Sep 03 |
| BIENAIME JEAN JACQUES | Director | Aug 14 '26 | Buy | 246.33 | 2,000 | 492,654 | 2,900 | Aug 18 |
| SMITH SCOTT THOMAS | EVP & Chief Financial Officer | Jun 02 '26 | Buy | 219.00 | 100 | 21,900 | 4,367 | Jun 02 |
| BIENAIME JEAN JACQUES | Director | May 29 '26 | Buy | 223.12 | 500 | 111,562 | 900 | Jun 01 |
| SMITH SCOTT THOMAS | EVP & Chief Financial Officer | May 29 '26 | Buy | 223.32 | 250 | 55,830 | 4,267 | Jun 01 |
| BIENAIME JEAN JACQUES | Director | May 26 '26 | Buy | 237.80 | 400 | 95,121 | 400 | May 27 |
| JENSEN FLEMMING STEEN | See Remarks | May 11 '26 | Sale | 238.49 | 19,460 | 4,641,021 | 0 | May 12 |